Medicare Coverage Guide for Pluvicto Treatment

What Pluvicto Is and How It Works

Pluvicto is a type of cancer treatment that the U.S. Food and Drug Administration (FDA) approved in March 2023. The full name is lutetium Lu 177 gozetotide. It is used to treat a specific type of prostate cancer that has spread to other parts of the body and no longer responds to certain hormone treatments.

Your Free Guide to NJ Natural Gas Bill Payment →

Pluvicto works differently than traditional chemotherapy. It is what doctors call a "radioligand therapy." This means the treatment uses a radioactive substance that attaches to cancer cells and delivers radiation directly to them. The treatment specifically targets cancer cells that have a particular protein marker called PSMA (prostate-specific membrane antigen). Before a patient receives Pluvicto, doctors perform a PET scan using a special imaging dye to confirm that the cancer cells have this marker. If the scan shows the marker is present, the patient may be a candidate for treatment.

The treatment involves intravenous infusions, typically given once every six weeks. Most patients receive between four and six treatments, though this can vary based on individual circumstances. Each infusion takes only a few minutes to administer, though patients must follow specific safety precautions during and after treatment because the substance is radioactive.

As of 2024, clinical trial data showed that patients receiving Pluvicto had improved survival outcomes compared to those who received different treatments. In the VISION trial, which studied over 800 patients, those who received Pluvicto plus standard hormone therapy showed a median overall survival benefit.

Practical Takeaway: Understanding that Pluvicto is a targeted radioligand therapy—not traditional chemotherapy—helps explain why your doctor may recommend it, how it differs from other treatments you may have tried, and what the treatment schedule typically involves. This information forms the foundation for understanding coverage decisions.

Medicare Coverage Basics for Pluvicto

Medicare is a federal health insurance program primarily for people age 65 and older, though some younger people with disabilities or end-stage renal disease also qualify. Medicare has several parts: Part A (hospital insurance), Part B (medical insurance), and Parts C and D (offered through private insurance companies).

Your Free Guide to Spectrum Bill Pay Login →

Pluvicto is covered by Medicare Part B when prescribed by a qualified oncologist for patients who meet certain medical criteria. Part B covers outpatient services, including most cancer treatments given in hospital outpatient departments or doctor's offices. Since Pluvicto is given as an outpatient infusion, Part B is the relevant coverage.

Medicare coverage does not mean the treatment is free. Patients with Original Medicare (Part A and Part B) typically pay a coinsurance amount—usually 20 percent of the approved cost after the Part B deductible is met. In 2024, the Part B deductible was $240. So if Pluvicto costs $20,000 per infusion and Medicare approves it at that rate, a patient would pay approximately $4,000 per infusion after the deductible, assuming no other factors apply.

Medicare's coverage of Pluvicto is based on FDA approval and supporting clinical evidence. The treatment must be medically necessary, meaning a qualified physician has determined it is appropriate for that patient's specific cancer diagnosis and medical history. Medicare does not cover treatments that are experimental, not FDA-approved, or determined to be not medically necessary for a particular patient.

If you have Medicare Advantage (Part C), coverage may differ from Original Medicare. Medicare Advantage plans are required to cover everything that Original Medicare covers, but they may have different cost-sharing amounts, prior authorization requirements, or network restrictions. Reviewing your specific plan documents is important.

Practical Takeaway: Pluvicto is a Part B covered benefit under Medicare when medically necessary and prescribed by a qualified provider. Understanding your specific Medicare plan type—Original Medicare or Medicare Advantage—helps you know what cost-sharing you may face and what authorization steps may be required before treatment begins.

Medical Eligibility Requirements and Criteria

While insurance coverage and medical necessity are related, they are not identical. Your insurance company covers something; medical necessity means your doctor has determined it is the right treatment for your specific situation. For Pluvicto, certain medical criteria must be present for treatment to be considered appropriate.

Free Guide to Golden Corral Senior Discount Pricing →

First, you must have a diagnosis of metastatic castration-resistant prostate cancer (mCRPC). "Metastatic" means the cancer has spread beyond the prostate to other parts of the body, typically bones or lymph nodes. "Castration-resistant" means the cancer continues to grow despite hormone therapy treatments that lower testosterone levels. These terms describe a specific stage and type of prostate cancer.

Second, the cancer cells must express the PSMA protein marker. This is confirmed through a PSMA PET imaging scan performed before treatment. Without this marker visible on imaging, Pluvicto cannot work effectively on the cancer cells. The scan must show moderate to high PSMA expression for the treatment to be appropriate.

Third, you must have already received or be unsuitable for certain other treatments. Typically, Pluvicto is given after patients have tried at least one other advanced hormone therapy or chemotherapy. This sequence is important because treatment is usually chosen based on what has been tried before and how the cancer responded.

Fourth, your overall health status must make you a suitable candidate. This includes adequate kidney and liver function, bone marrow function, and general performance status. Blood tests will be done to assess these factors. Patients with severe infections, uncontrolled heart disease, or certain other serious conditions may not be suitable candidates.

Your oncologist—the cancer specialist doctor—makes the final determination about whether you meet medical criteria for Pluvicto. This assessment is based on your individual medical records, imaging studies, lab results, and treatment history. Two different oncologists might reach different conclusions based on their clinical judgment and the specific details of your case.

Practical Takeaway: Understanding the medical criteria for Pluvicto—metastatic castration-resistant prostate cancer with PSMA expression, appropriate treatment sequencing, and adequate organ function—helps you have an informed conversation with your oncologist about whether this treatment is medically suitable for your situation.

The Prior Authorization Process

Prior authorization is a process where your doctor's office must contact your insurance company before starting a treatment to obtain advance approval. Medicare Part B generally does not require prior authorization for FDA-approved cancer drugs when prescribed by qualified providers, though some high-cost treatments may still be subject to additional review.

Learn About Building Meaningful Relationships and Connections →

If you have Original Medicare (Part A and Part B), your doctor's office will typically submit a claim to Medicare after Pluvicto is administered. Medicare then reviews the claim to verify that the patient had a covered diagnosis, that the treatment was prescribed by a qualified oncologist, and that the medical record supports the treatment as medically necessary. If everything is in order, Medicare processes the claim and pays its share.

If you have Medicare Advantage, prior authorization requirements vary by plan. Some Medicare Advantage plans require prior authorization before Pluvicto treatment begins. This means your oncology practice must contact your specific plan before the first infusion to obtain approval. The plan reviews your medical records, diagnosis, treatment history, and imaging to confirm the treatment meets their coverage criteria. This process typically takes a few business days but can sometimes take longer if additional information is needed.

The prior authorization request includes specific documents: pathology report confirming prostate cancer diagnosis, imaging reports showing metastatic disease, documentation of prior treatments, PSMA PET scan results, recent lab work showing kidney and liver function, and the oncologist's treatment plan and medical justification for Pluvicto.

If prior authorization is required and not obtained before treatment, the insurance company may deny the claim. This creates a financial problem because the patient or the treatment facility may be responsible for the full cost. This is why it is important for your doctor's office to check whether your specific plan requires prior authorization before scheduling the first infusion.

Once prior authorization is obtained (if required), it is typically valid for a specific time period, such as one year or for a specific number of infusions. If you need additional treatments beyond what was initially authorized, your doctor may need to request authorization for more infusions.

Practical Takeaway: Ask your oncology practice whether your Medicare plan requires prior authorization for Pluvicto and, if so, confirm that